摘要
目的:探讨分析艾迪注射液联合常规西医化疗对非霍奇金淋巴瘤患者的免疫和生存质量的影响。方法:选取非霍奇金淋巴瘤患者120例随机分为观察组和对照组,每组各60例。对照组患者接受常规西医化疗进行治疗,观察组患者同时联合艾迪注射液进行治疗。对比分析两组患者的临床疗效、免疫功能、不良反应发生情况和生存质量。结果:治疗前,两组患者的CD4^+、CD8^+和CD4^+/CD8^+水平与健康对照组比较,差异有统计学意义(P<0.05)。治疗后,观察组患者的CD4^+、CD8^+和CD4^+/CD8^+水平均明显优于对照组,差异有统计学意义(P<0.05)。观察组患者的临床有效率为51.67%(31/60),明显高于对照组35.00%(21/60),差异有统计学意义(P<0.05)。观察组患者的各项不良反应(血小板计数下降、恶心呕吐、白细胞计数下降和食欲不振)发生率均明显低于对照组,差异有统计学意义(P<0.05)。治疗后,对照组患者Karnofsky评分平均提高10分,其中提高14例,稳定23例,下降23例,提高率为23.33%(14/60);观察组患者Karnofsky评分平均提高15分,其中,提高28例,稳定14例,下降18例,提高率为46.67%(28/60)。观察组患者的生活质量变化高于对照组,差异有统计学意义(P<0.05)。结论:艾迪注射液联合常规西医化疗能够有效提高非霍奇金淋巴瘤患者的免疫功能和生活质量,同时能够有效降低不良反应的发生,提高患者的临床疗效。
Objective:To investigate the effect of Aidi Injection combined with conventional western medicine chemotherapy on immune and quality of life in patients with non-Hodgkin’s lymphoma.Methods:A total of 120 patients with non-Hodgkin’s lymphoma, were randomly divided them into observation group and control group, with 60 cases in each group. The patients in the control group were treated with conventional Western medicine chemotherapy, and those in the observation group were treated with Aidi Injection. The clinical efficacy, immune function, adverse reactions and quality of life of the two groups were compared and analyzed. Results:Before treatment, the levels of CD4^+, CD8^+ and CD4^+/CD8^+ in the two groups were significantly different from those in the healthy control group(P<0.05). After treatment,the CD4^+, CD8^+ and CD4^+/CD8^+ levels in the observation groupwere significantly better than those in the control group. And the difference was statistically significant(P<0.05). The clinical effective rate of the observation group was 51.67%(31/60), which was significantly higher than that of the control group[35.00%(21/60)]. The difference was statistically significant(P<0.05). The incidence of adverse reactions(decreased platelet count, nausea and vomiting, decreased white blood cell countand loss of appetite) in the observation group were significantly lower than those in the control group, and the difference was statistically significant(P<0.05). After treatment, the Karnofsky score of the control group increased by 10 points on average, of which 14 cases were improved, 23 cases were stableand 23 cases were decreased. The rate of increase was 23.33%(14/60). The observation group scored an average of 15 points for the Karnofsky score, among which, 14 cases were stable and 18 cases were decreased. The improvement rate was 46.67%(28/60). The quality of life of the observation group was higher than that of the control groupand the difference was statistically significant(P<0.05). Conclusions:Aidi Injection combined with conventional western medicine chemotherapy can effectively improve the immune function and quality of life of patients with non-Hodgkin’s lymphoma, and can effectively reduce the incidence of adverse reactions and improve the clinical efficacy of patients.
作者
汤计瑞
景莉
邢宏运
TANG Jirui;JING Li;XING Hongyun(Hematology Department,The Affiliated Hospital of Southwest Medical University,Luzhou 646000,Sichuan,China)
出处
《中华中医药学刊》
CAS
北大核心
2019年第8期2033-2035,共3页
Chinese Archives of Traditional Chinese Medicine
基金
四川省教育厅项目(16ZA0190)
